Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA, has secured acceptance from the United States Food and Drug Administration and the European Medicines Agency for regulatory review of PB016, its proposed biosimilar to Takeda Pharmaceutical Company Limited’s Entyvio. The applications cover a lyophilised vedolizumab formulation for intravenous administration in adults with moderately to severely active ulcerative colitis and Crohn’s disease.
The biologics licence application in the United States and the marketing authorisation application in Europe were submitted by Polpharma Biologics, which is responsible for developing and manufacturing PB016. Fresenius Kabi holds exclusive commercialisation rights across most global markets, excluding the Middle East and North Africa, subject to regulatory approvals.
Acceptance for review represents a meaningful regulatory milestone because it confirms that both agencies have received applications considered sufficiently complete to enter their formal assessment processes. It does not mean that PB016 has been approved, that biosimilarity has been established, or that regulators have reached conclusions regarding efficacy, safety, immunogenicity or manufacturing comparability.
For Fresenius, the development moves PB016 beyond the clinical-development stage and into a regulatory race involving a commercially important inflammatory bowel disease franchise. However, the potential opportunity comes with significant competitive and execution risks. Another proposed vedolizumab biosimilar has already entered United States review, Takeda continues to expand the Entyvio franchise, and PB016’s announced applications currently relate to the intravenous formulation rather than the increasingly important subcutaneous presentation.
Why FDA and EMA acceptance reduces filing risk without confirming that PB016 is biosimilar
The regulatory milestone removes an initial procedural uncertainty surrounding whether the applications would be accepted for assessment. It now allows regulators to examine the totality of evidence supporting PB016, including analytical comparability, biological activity, pharmacokinetics, immunogenicity, clinical performance and manufacturing controls.
Biosimilar review differs from the approval pathway for an entirely new biologic. The central question is not whether vedolizumab works as a therapeutic class, since that has already been established through the reference product. Regulators instead need to determine whether PB016 is highly similar to Entyvio, with no clinically meaningful differences in safety, purity or potency.
This makes analytical and manufacturing evidence particularly important. Even where clinical studies show comparable outcomes, regulators must be satisfied that the candidate’s molecular characteristics, production processes, impurities, stability and batch consistency support biosimilarity. The manufacturing component may be especially relevant because Polpharma Biologics, rather than Fresenius Kabi, is responsible for development and production.
Fresenius did not disclose an expected United States regulatory action date, a detailed European review timetable, or whether either agency had raised preliminary questions. The acceptance announcement therefore establishes that review has started, but it does not provide a reliable basis for predicting the final decision or launch date.
What does the disclosed PB016 evidence package reveal about the strength of the applications?
Fresenius said the regulatory submissions were supported by a comprehensive similarity programme that included analytical, non-clinical and clinical evidence. The programme included a Phase 1 study in healthy volunteers and a Phase 3 comparative trial involving adults with moderately to severely active ulcerative colitis.
Polpharma Biologics previously described the Phase 1 programme as a randomised, double-blind, three-arm study involving 120 healthy participants. The company reported that the trial supported pharmacokinetic and pharmacodynamic comparability between PB016 and reference vedolizumab, with no meaningful imbalances identified in the disclosed safety or immunogenicity findings. Those statements remain company-reported results rather than independently established regulatory conclusions.
The Phase 3 study was designed as a multicentre, randomised, double-blind comparison involving approximately 750 adults with moderately to severely active ulcerative colitis. Participants received PB016 or reference Entyvio, providing a clinical comparison intended to support the wider biosimilarity package.
The announcement did not provide detailed Phase 3 results, including equivalence margins, confidence intervals, clinical response rates, remission rates, treatment discontinuations, anti-drug antibody findings or comprehensive safety data. That absence does not indicate that the applications lack the information, but it limits the extent to which external observers can independently evaluate the clinical evidence before regulatory assessment is completed.
The proposed indications also include Crohn’s disease even though the disclosed comparative Phase 3 trial focused on ulcerative colitis. Such an approach can be consistent with biosimilar regulation, under which indications may be extrapolated when scientific justification, mechanism of action, pharmacology and the complete comparability package support the extension. Any extrapolation remains subject to the regulators’ assessment and should not be treated as automatic.
How does PB016’s intravenous formulation shape its potential commercial position?
PB016 is being reviewed as a lyophilised vial for intravenous administration. That places it directly against the established intravenous Entyvio presentation used in infusion centres and other supervised healthcare settings.
The intravenous market remains commercially relevant because treatment initiation, specialist oversight and infusion-based procurement continue to play important roles in inflammatory bowel disease care. In the United States, subcutaneous Entyvio maintenance follows initial intravenous dosing, which means the infusion channel remains connected to the wider franchise even as more patients gain access to self-administered maintenance options.
An intravenous biosimilar could appeal to healthcare systems, payers and infusion providers seeking lower acquisition costs or greater negotiating leverage. However, commercial adoption will depend on more than regulatory approval. Formulary positioning, reimbursement, contracting, physician familiarity, patient continuity, infusion-centre economics and the willingness of payers to encourage switching will all influence uptake.
PB016’s current intravenous-only positioning may also narrow its competitive flexibility. Takeda has expanded Entyvio through subcutaneous formulations and other lifecycle initiatives, while at least one competing biosimilar developer has submitted both intravenous and subcutaneous vedolizumab candidates in Europe.
This does not eliminate the opportunity for PB016, since an intravenous product can still compete for substantial institutional and payer-controlled volumes. It does mean that Fresenius Kabi may need to demonstrate attractive pricing, dependable supply and strong commercial access rather than relying on formulation breadth as its main differentiator.
How have Alvotech and Teva changed the first-wave vedolizumab biosimilar contest?
Fresenius and Polpharma Biologics are not entering an uncontested regulatory field. The United States Food and Drug Administration accepted Alvotech’s biologics licence application for AVT16, another proposed intravenous vedolizumab biosimilar, on June 8, 2026. Teva Pharmaceutical Industries Limited holds commercialisation responsibilities for that candidate in the United States.
Alvotech has also reported European Medicines Agency validation of an application covering AVT16 and AVT80, its proposed intravenous and subcutaneous vedolizumab biosimilars. That broader European formulation package could become commercially relevant if both candidates obtain authorisation and reach the market on competitive timelines.
The public timing of the Alvotech filing means PB016 cannot safely be described as the first proposed vedolizumab biosimilar to reach United States review. Fresenius had previously identified first-to-market potential in its internal strategic presentation, but the emerging regulatory sequence makes that objective less certain.
Submission timing alone will not determine the eventual commercial order. Regulatory questions, manufacturing inspections, intellectual-property arrangements, litigation, supply readiness and contracting decisions can move expected launch dates. A product filed later can still gain an advantage if its review, manufacturing preparation or market-access execution proceeds more smoothly.
Nevertheless, first-wave status matters. Payers and large healthcare organisations may establish preferred-product agreements early, particularly when several biosimilars arrive close together. Fresenius Kabi will therefore be competing not only against Takeda’s originator product, but also against other biosimilar manufacturers seeking the same initial contracting opportunities.
Why Takeda’s continued Entyvio growth raises the commercial bar for Fresenius
Entyvio remains one of Takeda Pharmaceutical Company Limited’s largest growth products. Takeda reported Entyvio revenue of 268.3 billion Japanese yen for the three months ended June 30, 2026, representing reported growth of 15.4 percent and constant-exchange-rate growth of 3.8 percent.
The product generated 958 billion Japanese yen during Takeda’s 2025 financial year, while the company forecast fiscal 2026 sales of approximately 1.046 trillion Japanese yen. These figures illustrate the size of the franchise that Fresenius, Alvotech and other prospective biosimilar entrants are targeting.
A large reference-product market can create substantial biosimilar potential, but it should not be confused with obtainable revenue. Takeda benefits from established prescriber familiarity, extensive clinical experience, payer relationships, multiple formulations and continuing lifecycle-development programmes.
The originator company has also continued pursuing paediatric indications and formulation expansion, strengthening Entyvio’s clinical and commercial footprint before major biosimilar competition emerges. These initiatives can protect portions of the franchise, reinforce physician familiarity and create differentiation that an intravenous-only biosimilar may not immediately replicate.
Fresenius Kabi’s commercial challenge will therefore be to convert lower-cost competition into sustainable share rather than simply secure approval. The outcome will depend on how aggressively payers promote biosimilar use, whether clinicians are comfortable switching stable patients, and whether manufacturers compete primarily through rebates, list-price reductions or institutional tenders.
What does the PB016 review milestone mean for Fresenius Kabi’s biopharma strategy?
Biopharma has become an increasingly important growth pillar for Fresenius. The company reported first-quarter 2026 biopharma revenue of €238 million, representing organic growth of approximately 34 percent, supported by the continued expansion of Tyenne and the launch progression of its denosumab biosimilars.
PB016 broadens that strategy by adding a potential immunology product addressing two major chronic inflammatory diseases. It also follows Fresenius Kabi’s existing biosimilar investments across autoimmune disease, oncology and bone health, creating an opportunity to leverage established market-access, regulatory and commercial infrastructure.
The licensing structure reduces the need for Fresenius to fund the entire development programme internally. At the same time, it introduces dependency on Polpharma Biologics for manufacturing quality, regulatory responses, production scale and reliable supply.
That division of responsibility makes coordination an important commercial factor. Fresenius Kabi may control much of the eventual market strategy, but it cannot independently solve a manufacturing inspection issue, comparability question or supply constraint arising within the development partner’s operations.
The regulatory acceptance should therefore be viewed as a medium-term pipeline de-risking event rather than an immediate earnings catalyst. PB016 cannot contribute meaningful product revenue until it obtains approval, clears intellectual-property and launch-timing barriers, establishes supply and secures market access.
Investor trading around the announcement also appeared measured rather than euphoric. Fresenius shares traded near €45 in late July, with a relatively modest same-day move. Available market data indicated positive five-day and one-month momentum, although the stock remained below its 52-week high, suggesting investors were balancing improving operating performance against the longer timelines attached to individual pipeline assets.
Which regulatory and commercial milestones will determine whether PB016 creates value?
The next important developments will be regulatory questions, manufacturing assessments and any eventual disclosure of detailed Phase 3 findings. Regulators may seek additional analytical, immunogenicity or chemistry, manufacturing and controls information before reaching a decision.
Inspection readiness at Polpharma Biologics’ manufacturing operations will be another critical variable. Biosimilar applications can be delayed even when clinical comparability appears adequate if regulators identify unresolved manufacturing, quality-system or facility-compliance issues.
Intellectual-property timing will also shape the commercial opportunity. Fresenius has previously identified 2029 as a potential loss-of-exclusivity benchmark for the Entyvio franchise, but actual launch timing may depend on jurisdiction-specific patents, settlements, litigation and regulatory exclusivities.
In the United States, interchangeability could become another competitive consideration. Alvotech has publicly described AVT16 as a proposed interchangeable biosimilar, while Fresenius’ announcement did not state that interchangeability was being sought for PB016. The practical impact would still depend on state substitution rules, payer policies and the realities of physician-administered biologic treatment.
Approval, should it be granted, would only begin the final commercial test. Fresenius Kabi and Polpharma Biologics would still need to provide dependable commercial-scale supply, price the product competitively, negotiate payer and infusion-centre access, and establish a credible position before early contracts become concentrated among rival biosimilars.
FDA and EMA acceptance has placed PB016 firmly inside the global vedolizumab biosimilar race. Its eventual value will be determined by whether the partners can convert a complete regulatory dossier into timely approvals, reliable manufacturing and meaningful market access while Takeda and competing biosimilar developers continue advancing their own strategies.
